Jardiance, Farxiga, and SGLT2 Inhibitors vs GLP-1s: Weight, Cardio-Renal Benefits, and Where Each Fits in 2026

SGLT2 inhibitors (empagliflozin/Jardiance, dapagliflozin/Farxiga, canagliflozin/Invokana) and GLP-1 receptor agonists (semaglutide/Ozempic/Wegovy, tirzepatide/Mounjaro/Zepbound, orforglipron/Foundayo) are the two type-2 diabetes drug classes that earned cardiovascular and kidney outcome indications over the last decade. Patient questions about which class causes more weight loss, which has the bigger heart-failure benefit, and whether they can be combined are common — and the published evidence answers them clearly. SGLT2 inhibitors produce approximately 2-3 kg of weight loss via urinary glucose excretion. GLP-1s produce 14-21% body weight reduction in dedicated obesity trials. Both classes have independent cardio-renal indications, and the trials and magnitudes are different in important ways. Here is the verified head-to-head map.

The two classes at a glance

SGLT2 inhibitors block sodium-glucose cotransporter 2 in the proximal renal tubule, causing the kidneys to excrete ~70 g of glucose per day in the urine (about 280 kcal/day). This produces a small but real caloric deficit and a smaller weight loss (typically 2-3 kg) than the caloric loss alone would predict, because compensatory hyperphagia partially offsets the deficit. The bigger story is the dramatic cardiovascular and kidney benefits that emerged from the cardiovascular outcomes trials starting with EMPA-REG OUTCOME in 2015^[1].

GLP-1 receptor agonists activate GLP-1 receptors in the pancreas (enhancing glucose-dependent insulin secretion), in the brain (reducing appetite), in the GI tract (slowing gastric emptying), and elsewhere. The weight loss is much larger — STEP-1 reported −14.9% body weight on semaglutide 2.4 mg^[14] and SURMOUNT-1 reported −20.9% on tirzepatide 15 mg^[15]. They also have parallel cardiovascular and kidney outcome trials (SUSTAIN-6, LEADER, SELECT, FLOW) that earned them indications independent of glycemic control.

The empagliflozin (Jardiance) trials

EMPA-REG OUTCOME (Zinman et al., NEJM 2015, n=7,020)^[1] randomized patients with type 2 diabetes and established cardiovascular disease to empagliflozin 10 mg, empagliflozin 25 mg, or placebo. The primary 3-point MACE endpoint was reduced with a hazard ratio of 0.86 (95% CI 0.74-0.99, p=0.04). Cardiovascular mortality was reduced by 38% (3.7% vs 5.9%), all-cause mortality was reduced by 32%, and heart failure hospitalization was reduced by 35%. The trial defined a new era in type 2 diabetes pharmacotherapy — for the first time, a glucose- lowering drug had been shown to reduce cardiovascular mortality in a dedicated outcome trial.

EMPEROR-Reduced (Packer et al., NEJM 2020, n=3,730)^[2] tested empagliflozin in patients with heart failure and reduced ejection fraction, with or without diabetes. The composite primary endpoint of cardiovascular death or heart failure hospitalization was reduced. EMPEROR- Preserved (Anker et al., NEJM 2021)^[3] then extended the benefit to heart failure with preserved ejection fraction with a hazard ratio of 0.79 (95% CI 0.69-0.90) — a critical finding because no other drug class had shown clear benefit in HFpEF. Together these trials made empagliflozin the first drug ever to receive FDA approval for both HFrEF and HFpEF.

The dapagliflozin (Farxiga) trials

DECLARE-TIMI 58 (Wiviott et al., NEJM 2019, n=17,160)^[4] tested dapagliflozin in a broader population of T2D patients than EMPA-REG — both with and without established cardiovascular disease. The MACE endpoint did not reach significance (HR 0.93, 95% CI 0.84-1.03), but heart failure hospitalization was reduced by 27% (HR 0.73, 95% CI 0.61-0.88). DECLARE established that the heart-failure benefit was a class effect even in patients without prior heart failure or established CVD.

DAPA-HF (McMurray et al., NEJM 2019, n=4,744)^[5] then tested dapagliflozin in dedicated heart- failure-with-reduced-EF patients (with or without diabetes) and replicated the heart-failure benefit. Worsening heart failure or cardiovascular death occurred in 16.3% (dapagliflozin) vs 21.2% (placebo). DAPA-CKD (Heerspink et al., NEJM 2020, n=4,304)^[6] then tested dapagliflozin in patients with chronic kidney disease (with or without diabetes) and reported a primary composite endpoint hazard ratio of 0.61 (95% CI 0.51-0.72, p<0.001) — a 39% reduction in sustained eGFR decline, end-stage kidney disease, or renal/cardiovascular death. DELIVER (Solomon et al., NEJM 2022, n=6,263)^[7] closed the loop by demonstrating benefit in heart failure with mildly reduced or preserved EF (HR 0.82, 95% CI 0.73-0.92, p<0.001).

The canagliflozin (Invokana) trials

CANVAS Program (Neal et al., NEJM 2017, n=10,142)^[8] reported a 14% reduction in 3-point MACE (HR 0.86, 95% CI 0.75-0.97, p=0.02) in T2D patients with established or high-risk CVD. The trial also produced a safety signal that has shaped the SGLT2 conversation since: a roughly doubled rate of lower-limb amputation (HR 1.97, 95% CI 1.41-2.75) in the canagliflozin arms vs placebo. The amputation signal was not replicated in subsequent SGLT2 trials with empagliflozin or dapagliflozin and is generally now considered a canagliflozin-specific concern, not a class effect. CREDENCE (Perkovic et al., NEJM 2019, n=4,401)^[9] then tested canagliflozin in T2D + nephropathy and reported a renal composite endpoint hazard ratio of 0.70 (95% CI 0.59-0.82, p<0.00001).

The GLP-1 cardio-renal trials

The GLP-1 class has its own four-trial cardio-renal evidence base. SUSTAIN-6 (Marso et al., NEJM 2016, n=3,297)^[10] tested semaglutide in T2D and reported a 26% reduction in the primary 3-point MACE endpoint (HR 0.74, 95% CI 0.58-0.95, noninferiority p<0.001). LEADER (Marso et al., NEJM 2016, n=9,340)^[11] tested liraglutide and reported MACE HR 0.87 (95% CI 0.78-0.97, p=0.01 for superiority). These were the first two GLP-1 trials to establish cardiovascular benefit in T2D patients with high CV risk.

SELECT (Lincoff et al., NEJM 2023, n=17,604)^[12] moved the question to people with obesity but without diabetes — closer to the population of GLP-1 patients in the obesity setting we cover most often. SELECT reported MACE HR 0.80 (95% CI 0.72-0.90, p<0.001)in patients with overweight/obesity and established CVD, without diabetes. This was the trial that earned semaglutide a cardiovascular indication independent of any diabetes diagnosis.

FLOW (Perkovic et al., NEJM 2024, n=3,533)^[13] then tested semaglutide in T2D + chronic kidney disease and reported a kidney composite endpoint hazard ratio of 0.76 (95% CI 0.66-0.88) — making semaglutide the first GLP-1 to earn an FDA-approved kidney indication. Our dedicated FLOW trial article walks through the design and the comparison with the SGLT2 kidney trials.

The weight-loss magnitude comparison

On the simplest comparison — how much weight does each class produce in dedicated trials — the difference is large:

• SGLT2 inhibitors: approximately 2-3 kg of weight loss in T2D outcome trials. The mechanism is urinary glucose excretion (~70 g/day = ~280 kcal/day), partially offset by compensatory hyperphagia. Weight loss generally plateaus by month 6 and is sustained but does not progress.
• Semaglutide 2.4 mg weekly (STEP-1): −14.9% body weight at 68 weeks (mean −15.3 kg from a baseline of ~105 kg)^[14].
• Tirzepatide 15 mg weekly (SURMOUNT-1): −20.9% body weight at 72 weeks (mean −21.9 kg)^[15].
• Orforglipron / Foundayo (ATTAIN-1): approximately −12.4% at the highest dose at 72 weeks. See our Foundayo approval deep-dive.

For weight loss alone, GLP-1s win by a factor of 5 to 10. But the comparison is not purely about weight: SGLT2 inhibitors are prescribed primarily for cardiovascular and kidney protection in T2D and HF patients, with weight loss as a secondary benefit. GLP-1s are now prescribed for cardiovascular protection too (SELECT), but the dominant indication for the higher doses (Wegovy, Zepbound) is obesity itself.

Combination therapy: SGLT2 + GLP-1

Because the two classes work through entirely different mechanisms, they are now routinely combined in T2D patients with both obesity and cardio-renal risk. The pivotal combination trial is DURATION-8 (Frías et al., Lancet Diabetes Endocrinol 2016, n=695)^[13], which randomized T2D patients on metformin to exenatide once-weekly, dapagliflozin once-daily, or both. The combination produced an A1c reduction of −2.0% versus −1.6% with exenatide alone and −1.4% with dapagliflozin alone, and additive weight loss. Subsequent trials and ADA Standards of Care now recommend combination SGLT2 + GLP-1 as first-line for T2D patients with established ASCVD, heart failure, or CKD whose A1c is more than 1.5-2.0 percentage points above goal.

Safety profiles

The two classes have distinct safety profiles. Patients comparing them should know:

• SGLT2 genital mycotic infections: approximately 3-5x baseline rates (about 6.4% on SGLT2 vs 1.8% on placebo in EMPA-REG, with women affected at higher rates than men). This is the most common SGLT2 side effect and is usually manageable with topical antifungals.
• SGLT2 euglycemic DKA: rare but real. The FDA issued a Drug Safety Communication in May 2015 highlighting cases of diabetic ketoacidosis with normal or mildly elevated blood glucose in SGLT2 users. Risk factors include insulin dose reductions, low-carbohydrate diets, severe illness, dehydration, and surgery.
• SGLT2 Fournier's gangrene: a very rare but serious necrotizing fasciitis of the perineum. The FDA added a boxed warning in August 2018. Postmarketing reports remain rare but serious enough that prescribers monitor for early signs (severe perineal pain, swelling, fever).
• SGLT2 amputation signal: seen in CANVAS for canagliflozin (HR 1.97), not replicated for empagliflozin or dapagliflozin in subsequent trials. Generally treated as a canagliflozin-specific concern.
• SGLT2 volume depletion: the diuretic effect can cause hypotension and dehydration, particularly in elderly patients on loop diuretics. Dose reductions of concomitant diuretics are commonly recommended at SGLT2 initiation.
• GLP-1 GI side effects: nausea, vomiting, diarrhea, and constipation are dose-dependent and most intense in the first 4-8 weeks. See our nausea management guide and verified trial side effects article.
• GLP-1 thyroid C-cell tumor signal (boxed warning in animals, no confirmed human signal). Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. See our thyroid cancer evidence article.
• GLP-1 pancreatitis signal: small numerical imbalance in some trials, generally accepted as a low- frequency but real adverse event. Patients with prior pancreatitis should discuss with their prescriber.

ADA Standards of Care 2025: where each class fits

The American Diabetes Association's 2025 Standards of Care recommend:

• T2D + established ASCVD: GLP-1 RA or SGLT2 inhibitor with proven CV benefit, independent of A1c.
• T2D + heart failure (especially HFrEF): SGLT2 inhibitor preferred (DAPA-HF, EMPEROR-Reduced, EMPEROR- Preserved, DELIVER). GLP-1 not specifically contraindicated but the SGLT2 evidence base is the deeper one for HF.
• T2D + CKD: SGLT2 inhibitor preferred up to eGFR threshold; semaglutide added in 2024 as an alternative based on FLOW.
• T2D + obesity: GLP-1 RA preferred for weight loss magnitude. SGLT2 may be added for cardio-renal protection.
• Initial combination therapy (SGLT2 + GLP-1) recommended for A1c >1.5-2.0% above goal or in patients with multiple high-risk indications.

The honest decision tree

For a patient with type 2 diabetes who wants substantial weight loss and cardio-renal protection, the answer is often both. For patients without diabetes who want primarily weight loss, GLP-1s (or for HF/CKD without diabetes, dapagliflozin or empagliflozin) are the answer:

• Primary goal: substantial weight loss. GLP-1 (semaglutide, tirzepatide, or orforglipron). SGLT2 will not deliver the magnitude.
• Primary goal: heart failure protection (with or without diabetes). SGLT2 inhibitor (dapagliflozin or empagliflozin). The HF evidence base is bigger for SGLT2 than for GLP-1.
• Primary goal: kidney protection in CKD (with diabetes). Either class. SGLT2 has more long-term data; semaglutide via FLOW now has an indication too.
• T2D + obesity + ASCVD or HF or CKD: SGLT2 + GLP-1 combination is increasingly the standard of care.
• Cost / access: SGLT2 inhibitors as a class are not yet generic in the US (as of 2026), and prices remain in the $500-800/month range at retail. GLP-1 access has improved with Foundayo at $149/month self-pay through LillyDirect. See our GLP-1 pricing index for current numbers.

Bottom line

• Weight loss magnitude: SGLT2 ~2-3 kg vs GLP-1 14-21%. GLP-1 wins by a factor of 5-10 on weight alone.
• Cardio-renal evidence: both classes have large outcome trials with favorable HRs. SGLT2 has the deeper heart failure evidence (DAPA-HF, EMPEROR series, DELIVER). GLP-1 has SUSTAIN-6, LEADER, SELECT, and now FLOW.
• Combination therapy (SGLT2 + GLP-1) is increasingly first-line in T2D + obesity + cardio-renal risk per ADA 2025.
• Safety: SGLT2 = genital infections, rare DKA, rare Fournier's, volume depletion. GLP-1 = GI side effects in the first 4-8 weeks, MTC contraindication, rare pancreatitis.
• Generic status as of 2026: none of the major SGLT2s are widely available as generics in the US; GLP-1 access has improved with Foundayo at $149/month self-pay through LillyDirect.

Related research and tools

• FLOW: how semaglutide became the first GLP-1 with a kidney indication
• SELECT: cardiovascular benefits of semaglutide in obesity without diabetes
• STEP-HFpEF: semaglutide in heart failure with preserved EF
• Foundayo vs Wegovy vs Zepbound: head-to-head comparison
• GLP-1 compounded pricing index
• GLP-1 side effects: verified trial rates

Important disclaimer. This article is educational and does not constitute medical advice. Patients with type 2 diabetes, heart failure, or chronic kidney disease should discuss class selection (SGLT2 inhibitor vs GLP-1 receptor agonist vs combination) with their prescribing clinician, who can weigh comorbidities, interactions, cost, and individual risk factors. Every primary source cited here was independently verified against PubMed by a research subagent on 2026-04-07. Specific HR/CI values cited are from published abstracts; full-text endpoints may differ slightly and should be confirmed against the trial publication for any critical clinical decision.